Skip to main navigation Skip to search Skip to main content

Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation

  • Jacob Busang
  • , Thembelihle Zuma
  • , Natsayi Chimbindi
  • , Nqobile Ngoma
  • , Carina Herbst
  • , Nonhlanhla Okesola
  • , Jaco Dreyer
  • , Theresa Smit
  • , Kristien Bird
  • , Lucky Mtolo
  • , Ngundu Behuhuma
  • , Limakatso Lebina
  • , Cheryl Hendrickson
  • , Jacqui Miot
  • , Willem Hanekom
  • , Kobus Herbst
  • , Janet Seeley
  • , Andrew Copas
  • , Kathy Baisley
  • , Maryam Shahmanesh*
  • LAPIS Study Team
*Corresponding author for this work
  • Africa Health Research Institute
  • University College London
  • University of KwaZulu-Natal
  • University of Pretoria
  • University of the Witwatersrand
  • University of Amsterdam
  • South African Medical Research Council
  • London School of Hygiene and Tropical Medicine

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Barriers and challenges associated with daily oral HIV pre-exposure prophylaxis (PrEP) contribute to poor uptake, low retention, and adherence rates among youth. Offering a choice of PrEP modalities integrated with peer support and delivered through community-based sexual and reproductive health (SRH) services will overcome these challenges. We describe the design of a trial to evaluate this approach at a population level. Methods: We are conducting a type 1a hybrid effectiveness, phase 3B, cluster randomised controlled trial (LAPIS) to evaluate the effectiveness and implementation of offering PrEP modality choices through community-based SRH services amongst youth aged 15–30 years living in rural Kwa-Zulu Natal, South Africa. LAPIS is nested within Thetha nami ngithethe nawe (Let’s Talk), an ongoing stepped-wedge trial with two periods investigating the effectiveness, implementation, and cost effectiveness of peer-led social mobilisation into decentralised integrated HIV and SRH services on the population prevalence of sexually transmissible HIV amongst youth. In the second period of Thetha nami, 40 trial clusters were randomised 1:1 to receive either a choice of PrEP modalities (oral PrEP, long-acting PrEP, i.e., two-monthly injectable cabotegravir (CAB LA) or dapivirine vaginal ring and HIV post-exposure prophylaxis [PEP] packs) or enhanced standard of care (ESoC) with oral PrEP only. All trial clusters are supported by peer navigators offering peer support and visited monthly by a mobile nurse-led clinic offering adolescent and youth-friendly HIV and SRH services. There are two primary outcomes: (1) effective uptake of PrEP or PEP, and (2) retention on PrEP, defined as attending at least one follow-up appointment after PrEP/PEP initiation, which are based on clinic data. Implementation outcomes are assessed using a mixed-methods and process evaluation following the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework. Discussion: LAPIS is a pragmatic trial to evaluate the addition of long-acting PrEP modalities to daily oral PrEP within community-based SRH services. By offering PrEP choices, LAPIS adopts a person-centred approach to improve adherence and retention among youth, including hidden key populations. Findings will provide insights into the real-world implementation of CAB-LA. Trial registration: ClinicalTrials.gov Identifier—NCT06250504. Registered: 01 February 2024.
Original languageEnglish
Article number610
JournalBMC public health
Volume26
Issue number1
DOIs
Publication statusPublished - 1 Dec 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 5 - Gender Equality
    SDG 5 Gender Equality

Keywords

  • Adolescents and young adults
  • Community-based sexual and reproductive health services
  • Dapivirine vaginal ring
  • Injectable cabotegravir
  • Long-acting PrEP
  • Peer support
  • Pragmatic trial

Fingerprint

Dive into the research topics of 'Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation'. Together they form a unique fingerprint.

Cite this